Evidence map›Paper›PMID 35252244›Full record

ArticleFrontiers in medicine2022

Pre-Clinical Study of the [

Jingya Han, Yang Chen, Yan Zhao, Xinming Zhao, Jingmian Zhang, Jianfang Wang, Zhaoqi Zhang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Frontiers in oncology · 2023
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Jingya HanDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yang ChenDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Yan ZhaoDepartment of Oncology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Xinming ZhaoDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jingmian ZhangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jianfang WangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zhaoqi ZhangDepartment of Nuclear Medicine, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Fourth Hospital of Hebei Medical University · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human epidermal growth factor receptor 2 (HER2) is an important biomarker in gastric cancer (GC) and directly influences the therapeutic effect. Fluorine is firmly bound to Al

Indexed as

affibodygastric cancerhuman epidermal growth factor receptor (HER2)molecular imagingmolecular probe

Identifiers

PMID35252244
PMCPMC8890119
OpenAlexW4213198133

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.